Sponsor hub
Dana-Farber Cancer Institute clinical trial failures
Review 86 stopped clinical trials from Dana-Farber Cancer Institute, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 11 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 47
- OTHER/UNKNOWN
- 27
- SAFETY
- 7
- EFFICACY/FUTILITY
- 4
- REGULATORY
- 1
Notable sponsors
- Dana-Farber Cancer Institute
- 86
Related phases
- Phase II
- 52
- Phase I
- 27
- Early Phase I
- 3
- Unknown
- 2
- Phase III
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 86 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
participants are no longer being examined or receiving intervention
Phase II Uveal Melanoma trial by Dana-Farber Cancer Institute. Stop reason: EFFICACY/FUTILITY.
This was a Simon two stage design trial that terminated after the first stage due to lack of response.
Phase II Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase I Lung Cancer Squamous Cell trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Funding and drug supply to continue the study are pending.
Phase II Lymphoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Low accrual
Phase II Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase II Non-small Cell Lung Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual, competing studies, and lack of efficacy
Phase II Mesothelioma trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Criteria not met for second stage at time of interim analysis
Phase II Bladder Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
In agreement with the drug sponsor and the institution, the trial has been terminated due to slow accrual.
Phase II Glioblastoma trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
safety concerns
Phase II Glioblastoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111 development program.
Phase I Recurrent Gynecological Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Expansion cohort was not open
Phase I Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Safety Implications
Phase I Pancreatic Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical trial.
Phase I Neuroblastoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Manufacturing issues
Phase I Follicular Lymphoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.
Phase IV Liver Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
No participants enrolled. Inability to perform intraprocedural MRI with the intraarterial infusion catheter in place due to MRI incompatibility.
Phase III Prostate Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
PI is terminating the study due to slow/low accrual
Phase II Ewing Sarcoma trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
The study closed early due to discontinuation of ganitumab supply.
Phase II Multiple Myeloma trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Study support withdrawn
Phase I Waldenstrom's Macroglobulinemia trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Sponsor decision to end follow-up early
Phase II Carcinoma, Non-Small-Cell Lung trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Funding was pulled
Phase II Melanoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Due to poor enrollment
Phase I Diffuse Intrinsic Pontine Glioma trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Withdrawal of support from BMS
Phase II Solid Tumor trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Difficulty with patient recruitment
Phase II Recurrent Metastatic Melanoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Principal Investigator left the institute
Phase II CLL trial by Dana-Farber Cancer Institute. Stop reason: EFFICACY/FUTILITY.
Terminated early due to change in practice.
Phase II Unresectable Melanoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Study terminated by sponsor
Phase II Merkel Cell Carcinoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Lack of accrual.
Phase II T-cell Non-Hodgkin Lymphoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual and futility
Phase II Myelodysplastic Syndrome trial by Dana-Farber Cancer Institute. Stop reason: EFFICACY/FUTILITY.
Recommendation by the Data and Safety Monitoring Board due to efficacy concerns
Phase I Metastatic Non-hematologic Malignancies trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Early Phase I Radiation Dermatitis trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Lack of patient accrual in the past year.
Phase II Lymphoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Funding terminated
Phase II Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
The study was terminated early due to slow accrual.
Phase II Invasive Breast Cancer (Stage I-III) trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
no enough patients
Phase I Tumors of the Central Nervous System trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Large phase II opened to accue same patients
Phase I ALK-positive Non-small Cell Lung Cancer (NSCLC) trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Study closed due to slow accrual and lack of efficacy.
Phase II Metastatic Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Based on two-stage design, the study ended at stage 1 with no evidence of promise based on pre-specified decision rule.
Phase I Waldenstrom's Macroglobulinemia trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Per protocol, Phase II is to be terminated early if a less than 5% of the Phase II participants observe a Very Good Partial Response or Better in the first 23 participants enrolled to Phase II.
Phase I Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Study halted prematurely, prior to enrollment of first participant.
Unknown Soft Tissue Sarcoma trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Inability to accrue.
Phase II Pancreatic Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Sponsorship for trial was halted after company acquisition
Phase II Prostate Cancer trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
Safety concerns
Phase I Chronic Lymphocytic Leukemia trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Business development reasons.
Phase II Melanoma Stage III trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase II Bladder Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Withdrawn per Bayer
Phase II Epidermal Growth Factor Receptor trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Terminated due to Osimertinib approval
Phase I Ovarian Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Company decided not to move forward with further accrual.
Phase I Acute Myeloid Leukemia trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Cervical Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Drug supply
Phase I Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Insufficient Resources
Phase I Prostate Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Due to slow accrual the supllier of BKM120 asked we cease further enrollment.
Phase II Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Not enough confirmed responses to continue treatment.
Phase I Non Hodgkin Lymphoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
slow accrual
Phase II Rectal Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase II HER2-positive Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
The study terminated early due to weak accrual.
Phase II Ovarian Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Early closure based on audit by study investigators after 3 patients died on study.
Phase I Ovarian Cancer trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
Terminated due to unacceptable toxicity
Phase I Prostate Cancer trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
The study terminated early due to concerns about drug toxicity.
Phase II Multiple Myeloma trial by Dana-Farber Cancer Institute. Stop reason: REGULATORY.
Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs.
Phase II Chronic Graft-versus-Host-Disease trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Due to slow accrual, study team has decided to end the study early.
Unknown Lung Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Co-investigator left facility. Decided not to enroll patients therefore.
Phase I Pancreatic Cancer trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
Excess toxicity was identified intraoperatively
Phase II Squamous Cell Carcinoma of the Head and Neck trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Due to slow accrual
Phase I Squamous Cell Carcinoma of the Head and Neck trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions.
Phase II Sickle Cell Disease trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
The study terminated early due to slow accrual.
Phase I Multiple Myeloma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Study was never open due to lack of funding
Early Phase I Leukemia trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase II Ovarian Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
due to slow accrual
Phase II Melanoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
due to weak accrual
Phase II Thrombocytopenia trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Low accrual.
Early Phase I T-Cell Lymphoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase II Head and Neck Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow Accrual
Phase II Breast Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Not enough responses to continue treatment.
Phase II Waldenstrom's Macroglobulinemia trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
Safety issues from trials in CLL
Phase II Pleural Mesothelioma trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
lack of acurral
Phase II Solid Tumor trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Development of BAY1000394 has been terminated by Bayer.
Phase I Chronic Lymphocytic Leukemia trial by Dana-Farber Cancer Institute. Stop reason: EFFICACY/FUTILITY.
lack of efficacy and tolerability
Phase I Esophageal Cancer trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
Awaiting additional safety data
Phase II Waldenstrom's Macroglobulinemia trial by Dana-Farber Cancer Institute. Stop reason: SAFETY.
Toxicity
Phase II Malignant Glioma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Merck (supplier of study drug \& funding) has undergone a large reprioritization, in which they had to terminate many oncology trials, including this one.
Phase II Waldenstrom's Macroglobulinemia trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual led to early study termination.
Phase II Invasive Breast Carcinoma trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual
Phase II Langerhans Cell Histiocytosis trial by Dana-Farber Cancer Institute. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Non-small Cell Lung Cancer trial by Dana-Farber Cancer Institute. Stop reason: OPERATIONAL.
Slow accrual due to restrictive eligibility criteria